Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Intravenous

Intravenous

22

Pipeline Programs↗

26

Active Trials↗

82

Companies Involved↗

Intravenous is an emerging landscape with 22 programs across 82 companies. The most active players are Meiji Pharma USA Inc.. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

30/100

Mech. Concentration

25/100

Completion Rate

90/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Meiji Pharma USA Inc.

1 program

Pipeline

Programs by Phase

Preclinical14

Rocuronium

Fresenius Kabi USA, LLC

Visipaque

GE Healthcare

Isosorbide Dinitrate

AstraZeneca

Selected Apelin Dose

University Hospital, Basel, Switzerland

Amoxicillin/ca

RESnTEC, Institute of Research

Phase 13

ALTB-268

AltruBio Inc.

ME3241

Meiji Pharma USA Inc.

ZMA001 (BC-NKA-20008)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 22

Sodium Valproate

AstraZeneca

Oxytocin

Retrophin

Phase 33

Magnesium SO4

Hospital de Base

Injectafer

American Regent, Inc.

IV Thyroxin

Rambam Health Care Campus

Approved

No programs

Analysis

Trial Status

535

clinical trials

Completed420 · 79%

Unknown status37 · 7%

Terminated32 · 6%

Recruiting12 · 2%

Withdrawn11 · 2%

Not yet recruiting7 · 1%

Other16 · 3%

Clinical Trials

Trial Activity

535 trials

Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment

Recruiting·AAzienda Sanitaria Universitaria Friuli Centrale·Phase 2·NCT07481539·240 enrolled

Intranasal Versus Intravenous Fentanyl For Procedural Analgesia in Preterm Neonates

Recruiting·—·Phase 1·NCT07190625·75 enrolled

Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants

Recruiting·AAltruBio Inc.·Phase 1·NCT07350577·24 enrolled

Subcutaneous Infliximab After A Previous Intravenous Dose Optimization

Recruiting·BBelgian Inflammatory Bowel Disease Research and Development (BIRD) VZW·Phase 4·NCT06113913·275 enrolled

Study of Intravenous ZMA001 in Healthy Subjects

Recruiting·National Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT05967299·96 enrolled

Pediatric Intravenous Contrast-Enhanced Ultrasound(CEUS) in China

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·N/A·NCT07113808·108 enrolled

Anabolic Response To Intravenous Amino Acids In Chronic Intestinal Failure Patients

Recruiting·IInstitute of Oncology Ljubljana·N/A·NCT07422792·40 enrolled

Effects Of Intravenous Oxytocin On Peripheral Sensory Afferents Using Microneurography

Recruiting·WWake Forest University Health Sciences·Phase 2·NCT07409753·60 enrolled

Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT07444788·40 enrolled

Ketorolac Intravenous Regional Analgesia in Lower Limb Surgeries

Recruiting·MMansoura University·N/A·NCT05543785·76 enrolled

Intravenous Iron Effects on Performance at High Altitude

Recruiting·—·Phase 4·NCT06686693·24 enrolled

Intravenous Hydromorphone for the Treatment of Acute Pain

Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1/2·NCT06949059·30 enrolled

A Pooled Analysis of Long-Term Outcomes After Inhaled Isoflurane Via the Sedaconda ACD-S Compared to Intravenous Propofol

Active, not recruiting·SSedana Medical·Phase 3·NCT06809218·312 enrolled

The Effect of Continuous Intravenous Infusion of Lidocaine on PPCs and Prognosis in Emergency Surgical Patients With IAI

Active, not recruiting·SShanghai Zhongshan Hospital·N/A·NCT06304779·428 enrolled

VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study (DOPER)

Active, not recruiting·GGroupe d'Etude Therapeutique des Affections Inflammatoires Digestives·N/A·NCT05158517·349 enrolled

Page 1 of 36

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)